FDA, Merck, and Vioxx : putting patient safety first? : hearing before the Committee on Finance, United States Senate, One Hundred Eighth Congress, second session, November 18, 2004.

Merck : pricing Gardasil /
by: Calkins, Tim, et al.
Published: (2016)

Merck & Co : after Vioxx, the government and the pharmaceutical industry reconsider the balance between innovation, safety, and cost /
by: Elias, Jaan, et al.
Published: (2016)

Risk and responsibility : the roles of FDA and pharmaceutical companies in ensuring the safety of approved drugs, like Vioxx : hearing before the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, first session, May 5, 2005.
Published: (2005)

The moral corporation--Merck experiences /
by: Vagelos, P. Roy
Published: (2006)

Lehman Brothers research : an analyst decides that the market overreacted to Merck's Vioxx woes /
by: Hutchins, Spencer
Published: (2016)

Networks of innovation : vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 /
by: Galambos, Louis
Published: (1995)

Drug tests : products to defraud drug use screening tests are widely available : testimony before the Chairman, Subcommittee on Oversight and Investigations, Committeee on Energy and Commerce, House of Representatives /
by: Cramer, Robert J.
Published: (2005)

Subversion of drug testing programs : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Ninth Congress, first session, May 17, 2005.
Published: (2005)

Subversion of drug testing programs : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Ninth Congress, first session, May 17, 2005.
Published: (2005)

Penalties for illegal activities in the approval of drugs : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, second session, on H.R. 4810 ... June 28, 1990.
Published: (1990)

FDA's Faulty Safeguards Against Corruption : Concerns over Debarment Use and Authority.
Published: (2008)

The moral corporation /
by: Vagelos, P. Roy
Published: (2006)

The firm and the FDA : McKinsey & Company's conflicts of interest at the heart of the opioid epidemic : interim majority staff report /
Published: (2022)

Challenges for the FDA : the future of drug safety : workshop summary /
Published: (2007)

Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on Sterility Test General Chapter.

Staff report on Sanofi's strategic use of third parties to influence the FDA /
Published: (2011)

Ketek clinical study fraud : what did Aventis know? : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, February 12, 2008.
Published: (2008)

Ketek clinical study fraud : what did Aventis know? : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, February 12, 2008.
Published: (2008)

60 minutes.
Published: (2004)

FDA drug approval : review time has decreased in recent years : report to congressional requesters.
Published: (1995)

Analytical methods for therapeutic drug monitoring and toxicology /
by: Xu, Quanyun A., 1961-
Published: (2011)

FDA and the drug development process : how the agency ensures that drugs are safe and effective.
Published: (2002)

FDA-approved bargain drugs : generic products must meet high standards.
Published: (2003)

Drug safety evaluation /
by: Gad, Shayne C., 1948-, et al.
Published: (2023)

FDA user fees 2012 : how innovation helps patients and jobs : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, April 18, 2012.
Published: (2013)

The FDA Commission : the delegation of authority to state and local authorities.
Published: (1989)

The FDA Commission : the delegation of authority to state and local authorities.
Published: (1986)

FDA almanac.

Clinical pharmacokinetics /
Published: (2006)

FDA is issuing more postmarketing requirements, but challenges with oversight persist.
Published: (2016)

FDA's generic drug enforcement and approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, March 7 and June 5, 1991.
Published: (1992)

FDA review times : statement of Mary R. Hamilton, Director of Program Evaluation in Human Services Areas, Program Evaluation and Methodology Division, before the Subcommittee on Health and Environment, Committee on Commerce, House of Representatives.
by: Hamilton, Mary R. (Mary Ruth), 1944-
Published: (1996)

FDA checkup : drug development and manufacturing challenges : hearing before the Subcommittee on Energy Policy, Health Care and Entitlements of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Thirteenth Congress, first session, December 12, 2013.
Published: (2014)

Clinical challenges in therapeutic drug monitoring : special populations, physiological conditions and pharmacogenomics /
Published: (2016)

FDA administrative enforcement manual /
by: Parker, Florence R.
Published: (2005)

FDA's drug approval process : up to the challenge? : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, first session, on examining Food and Drug Administration's (FDA) drug approval process, focusing on FDA's drug approval process after a sponsor demonstrates that their benefits outweigh their risks for a specific population and use, and that the drug meet [as printed] meets standards for safety and efficacy, March 1, 2005.
Published: (2005)